Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
April 28, 2024 at 03:33 am EDT
Share
Honz Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was CNY 104.74 million compared to CNY 174.6 million a year ago. Revenue was CNY 104.74 million compared to CNY 174.6 million a year ago.
Net loss was CNY 46.5 million compared to net income of CNY 15.41 million a year ago. Basic loss per share from continuing operations was CNY 0.1033 compared to basic earnings per share from continuing operations of CNY 0.0343 a year ago. Diluted loss per share from continuing operations was CNY 0.1033 compared to diluted earnings per share from continuing operations of CNY 0.0343 a year ago.
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.